Seeking Alpha

Vivus (VVUS) +6.8% premarket after a study concludes its weight-loss drug Qsymia significantly...

Vivus (VVUS) +6.8% premarket after a study concludes its weight-loss drug Qsymia significantly improved multiple cardiovascular disease risk factors. The biopharma company says patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors.
From other sites
Comments (1)
  • billchristie
    , contributor
    Comments (23) | Send Message
     
    Here is the Study published in The American Journal of Cardiology: "Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index ≥27 kg/m2."

     

    http://bit.ly/WFFTTD
    Catch me on twitter @BAMPOTSCOT
    1 Feb 2013, 10:59 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs